Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FHND9041 versus afatinib as first-line therapy for EGFR-mutant advanced non-small cell lung cancer
ChiCTR2100050397Phase 3Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of FHND-9041 and afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Aug 2021; status: recruiting.
02
Drugs
FHND-9041afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100050397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050397.